OncoDiag Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 5

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $3.01M

  • Investors
  • 6

OncoDiag General Information

Description

Developer of non-invasive diagnostic testing kits designed to help in the early detection of urological cancers. The company's testing kits consist of a urine-based lab test for the surveillance of bladder cancer, a tissue-based lab test to predict non-evolutive localized prostate cancer, and a blood-based lab test for screening colorectal cancer, enabling doctors to effectively proceed in cancer diagnostics.

Contact Information

Website
www.oncodiag.fr
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Biotechnology
Clinics/Outpatient Services
Corporate Office
  • 9 Rue de Pacy
  • 27930 Miserey
  • France
+33 02 00 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

OncoDiag Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series A) 15-Mar-2021 $3.01M 000 00.000 Completed Generating Revenue
3. Angel (individual) 14-Dec-2018 00000 00000 00.000 Completed Generating Revenue
2. Angel (individual) 06-Jun-2017 $207K $207K 00.000 Completed Generating Revenue
1. Accelerator/Incubator 05-Jun-2014 Completed Generating Revenue
To view OncoDiag’s complete valuation and funding history, request access »

OncoDiag Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 00,000 00.000000 000.00 000.00 00 000.00 00.000
Ordinary 00,000 00.000000 000.00 000.00 00 000.00 00.000
Ordinary 9,300 $1.204024 $24.08 $24.08 1x $24.08 5.96%
To view OncoDiag’s complete cap table history, request access »

OncoDiag Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of non-invasive diagnostic testing kits designed to help in the early detection of urological cancers. The com
Diagnostic Equipment
Miserey, France
5 As of 2023
000
0.000 0000-00-00
00000000000 000

000000

elit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupida
0000000000 00000000
Pleasanton, CA
000 As of 0000
0000
000000000000

000000

sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad m
0000000000 000000000
Boulder, CO
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

OncoDiag Competitors (5)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
DiaCarta Venture Capital-Backed Pleasanton, CA 000 0000 000000000000
Biodesix Formerly VC-backed Boulder, CO 000 00000 000000000 00000
OncoCyte Pending Transaction (M&A) Irvine, CA 00 000.00 000000000 000.00
Owlstone Medical Venture Capital-Backed Cambridge, United Kingdom 000 00000 00000000000 00000
Nucleix Venture Capital-Backed Rehovot, Israel 00 000.00 00000000000 000.00
You’re viewing 5 of 5 competitors. Get the full list »

OncoDiag Patents

OncoDiag Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
ES-2730710-T3 Methods for surveillance, diagnosis and exploration of bladder cancer (bladder) Active 19-Nov-2013 0000000000
US-20190062849-A1 Methods for the surveillance, diagnosis and screening of bladder cancer Active 19-Nov-2013 0000000000
US-11060152-B2 Methods for the surveillance, diagnosis and screening of bladder cancer Active 19-Nov-2013 0000000000 0
US-20160273048-A1 Methods for the surveillance, diagnosis and screening of bladder cancer Inactive 19-Nov-2013 0000000000
EP-2873740-A1 Methods for the surveillance, diagnosis and screening of bladder cancer Inactive 19-Nov-2013 C12Q1/6886 0
To view OncoDiag’s complete patent history, request access »

OncoDiag Executive Team (2)

Name Title Board Seat Contact Info
Claude Hennion Ph.D Co-Founder, President & Chief Executive Officer
Jean-Pierre Roperch Ph.D Co-Founder & Director of Research & Development
To view OncoDiag’s complete executive team members history, request access »

OncoDiag Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

OncoDiag Investors (6)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Normandie Participations Venture Capital Minority 000 0000 000000 0
Paris Business Angels Angel Group Minority 000 0000 000000 0
SFINE Corporation Minority 000 0000 000000 0
Angels Santé Angel Group Minority 000 0000 000000 0
Normandie Business Angels Angel Group Minority 000 0000 000000 0
You’re viewing 5 of 6 investors. Get the full list »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »